evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Necrotising enterocolitis · promoting growth and development in very low birth weight infants receiving human milk

The review found no eligible studies for this question.

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Culture‐proven late‐onset sepsis · promoting growth and development in very low birth weight infants receiving human milk

The review found no eligible studies for this question.

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Bronchopulmonary dysplasia · promoting growth and development in very low birth weight infants receiving human milk

It is very uncertain whether targeted or adjustable individualized fortification changes bronchopulmonary dysplasia compared with standard non‐individualized fortification (very low certainty).

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Retinopathy of prematurity · promoting growth and development in very low birth weight infants receiving human milk

It is very uncertain whether targeted or adjustable individualized fortification changes retinopathy of prematurity, any compared with standard non‐individualized fortification (very low certainty).

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Presence of osteopenia · promoting growth and development in very low birth weight infants receiving human milk

It is very uncertain whether targeted or adjustable individualized fortification changes osteopenia compared with standard non‐individualized fortification (very low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

External uterine compression (all methods) plus normal care vs normal care

Mortality due to bleeding ‐ not reported · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601

The review found no eligible studies for this question.

1 finding from 1 review